Utilisation de certaines médications cardiologiques dans le traitement de la schizophrénie: revue de la littérature.

Por Llorca, P M, Wolf, M A
Publicado em 1991

Manic behaviour induced by deep‐brain stimulation in Parkinson's disease: evidence of substantia nigra implication?

Por Ulla, M, Thobois, S, Lemaire, J‐J, Schmitt, A, Derost, P, Broussolle, E, Llorca, P‐M, Durif, F
Publicado em 2006

Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsy...

Por Schreiner, A, Bergmans, P, Cherubin, P, Keim, S, Llorca, P-M, Cosar, B, Petralia, A, Corrivetti, G, Hargarter, L
Publicado no J Psychopharmacol (2015)

A double amino-acid change in the HLA-A peptide-binding groove is associated with response to psychotropic treatment in patients with schizophrenia

Por Le Clerc, S, Taing, L, Fond, G, Meary, A, Llorca, P-M, Blanc, O, Beaune, P, Rajagopal, K, Jamain, S, Tamouza, R, Zagury, J-F, Leboyer, M
Publicado no Transl Psychiatry (2015)

CAGE, RAPS4, RAPS4-QF and AUDIT Screening Tests for Men and Women Admitted for Acute Alcohol Intoxication to an Emergency Department: Are Standard Thresholds Appropriate?

Por Geneste, J., Pereira, B., Arnaud, B., Christol, N., Liotier, J., Blanc, O., Teissedre, F., Hope, S., Schwan, R., Llorca, P.M., Schmidt, J., Cherpitel, C.J., Malet, L., Brousse, G.
Publicado em 2012

Hallucinations in schizophrenia and Parkinson’s disease: an analysis of sensory modalities involved and the repercussion on patients

Por Llorca, P. M., Pereira, B., Jardri, R., Chereau-Boudet, I., Brousse, G., Misdrahi, D., Fénelon, G., Tronche, A.-M., Schwan, R., Lançon, C., Marques, A., Ulla, M., Derost, P., Debilly, B., Durif, F., de Chazeron, I.
Publicado no Sci Rep (2016)